罗沙司他联合重组人促红素治疗慢性肾衰竭合并肾性贫血的临床研究  

The effect of roxadustat combined with recombinant human erythropoietin on the curative effect,micro-inflammatory state and iron metabolism in patients with chronic renal failure complicated with renal anemia

作　　者：王一郎 王红霞 冯秀芳 Wang Yilang;Wang Hongxia;Feng Xiufang(Department of Nephrology,Yiwu Fuyuan Hospital,Yiwu 322000,China;Department of General Surgery,the Fourth Affiliated Hospital of Medical College of Zhejiang University,Yiwu 322000,China)

机构地区：[1]义乌復元医院肾内科,义乌322000 [2]浙江大学医学院附属第四医院普外科,义乌322000

出　　处：《中国医师进修杂志》2024年第12期1104-1107,共4页Chinese Journal of Postgraduates of Medicine

摘　　要：目的探讨罗沙司他胶囊、重组人促红素(rhEPO)联合用药治疗慢性肾衰竭合并肾性贫血的临床疗效。方法前瞻性选择2019年10月至2022年10月在义乌復元医院接受治疗的慢性肾衰竭合并肾性贫血患者105例,按随机数字表法分为观察组(53例)和对照组(52例),两组均接受维持性血液透析治疗,对照组给予rhEPO静脉注射治疗,观察组在对照组治疗的基础上联合罗沙司他胶囊口服治疗,两组均连续治疗8周后判定临床疗效,并比较两组贫血指标、微炎性因子指标、铁代谢指标水平的差异。结果观察组总有效率高于对照组[96.23%(51/53)比80.77%(42/52)],差异有统计学意义(χ^(2)=4.46,P<0.05)。观察组治疗后血红蛋白、红细胞、红细胞压积高于对照组[(102.54±9.37)g/L比(91.82±10.20)g/L、(3.62±0.59)×10^(12)/L比(2.77±0.63)×10^(12)/L、0.369±0.068比0.288±0.056],差异有统计学意义(P<0.05)。观察组治疗后肿瘤坏死因子-α、C-反应蛋白、白细胞介素6低于对照组[(2.14±0.56)μg/L比(3.26±0.72)μg/L、(8.17±2.44)mg/L比(10.73±3.05)mg/L、(101.27±14.95)μg/L比(123.74±18.38)μg/L],差异有统计学意义(P<0.05)。观察组治疗后血清铁蛋白、转铁蛋白、转铁蛋白饱和度高于对照组,铁调素低于对照组[(288.47±26.65)μg/L比(259.66±24.80)μg/L、(2.81±0.31)g/L比(2.43±0.35)g/L、0.351±0.051比0.299±0.053、(95.17±17.56)μg/L比(106.49±19.28)μg/L],差异有统计学意义(P<0.05)。结论罗沙司他联合rhEPO治疗慢性肾衰竭合并肾性贫血疗效显著,可有效改善患者体内微炎性反应状态和铁代谢指标,缓解贫血症状。ObjectiveTo study the clinical efficacy of roxadustat capsule combined with recombinant human erythropoietin(rhEPO)in the treatment of chronic kidney failure(CKD).MethodsA total of 105 patients with CKD complicated with renal anemia who received treatment in Yiwu Fuyuan Hospital from October 2019 to October 2022 were prospectively selected and divided into observation group(53 cases)and control group(52 cases)according to random number table method.Both groups received maintenance hemodialysis treatment,while the control group received rhEPO intravenous injection treatment.On the basis of the control group,the observation group received roxadustat oral treatment.After 8 weeks of continuous treatment,the clinical efficacy of both groups was determined,and the anemia indicators,micro inflammatory factors and iron metabolism indicators were compared.ResultsThe total effective rate in the observation group was higher than that in the control group:96.23%(51/53)vs.80.77%(42/52),there was statistical difference(χ^(2)=4.46,P<0.05).After treatment,the levels of hemoglobin(Hb),red blood cell(RBC)and hematocrit(Hct)in the observation group were higher than those in the control group:(102.54±9.37)g/L vs.(91.82±10.20)g/L,(3.62±0.59)×10^(12)/L vs.(2.77±0.63)×10^(12)/L,0.369±0.068 vs.0.288±0.056,there were statistical differences(P<0.05).After treatment,the levels of tumor necrosis factor-α,C-reactive protein and interleukin-6 in the observation group were lower those in the control group:(2.14±0.56)μg/L vs.(3.26±0.72)μg/L,(8.17±2.44)mg/L vs.(10.73±3.05)mg/L,(101.27±14.95)μg/L vs.(123.74±18.38)μg/L,there were statistical differences(P<0.05).After treatment,The levels of ferritin,transferrin,transferrin saturation in the observation group were higher than those in the control group and hemodulin was lower than that in the control group:(288.47±26.65)μg/L vs.(259.66±24.80)μg/L,(2.81±0.31)g/L vs.(2.43±0.35)g/L,0.351±0.051 vs.0.299±0.053,(95.17±17.56)μg/L vs.(106.49±19.28)μg/L,there were statistical

关 键 词：肾功能不全 贫血 罗沙司他 重组人促红素 治疗结果 

分 类 号：R692.5[医药卫生—泌尿科学] R556[医药卫生—外科学]